{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:19:11Z","timestamp":1780481951203,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.10.014","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T03:28:40Z","timestamp":1762572520000},"page":"73-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u201cUpfront Use of Blinatumomab in Adolescents and Adults With Philadelphia Chromosome: Negative B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Proportional Meta-Analysis\u201d"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3662-8540","authenticated-orcid":false,"given":"Henri","family":"Fero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frenki","family":"Gjika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piro","family":"Paparisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Faccin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Isabel","family":"Borre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Trako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alabbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2025.10.014_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"issue":"27","key":"10.1016\/j.clml.2025.10.014_bib0002","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2025.10.014_bib0003","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"issue":"9617","key":"10.1016\/j.clml.2025.10.014_bib0004","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.10.014_bib0005","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.10.014_bib0006","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.10.014_bib0007","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.014_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101208","article-title":"Advances in the treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"66","author":"Burkart","year":"2024","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.clml.2025.10.014_bib0009","first-page":"131","article-title":"Treatment of older adults with acute lymphoblastic leukemia: challenges and future directions","volume":"2014","author":"Fielding","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.clml.2025.10.014_bib0010","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2014-09-551937","article-title":"How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"126","author":"Frey","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.10.014_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.10.014_bib0012","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9881","key":"10.1016\/j.clml.2025.10.014_bib0013","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2025.10.014_bib0014","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Philadelphia chromosome\u2013like acute lymphoblastic leukemia","volume":"129","author":"Pui","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.10.014_bib0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41408-024-01179-4","article-title":"Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab","volume":"14","author":"Jabbour","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.10.014_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101208","article-title":"Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia","volume":"66","author":"Burkart","year":"2024","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.clml.2025.10.014_bib0017","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.10.014_bib0018","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/21645515.2018.1540828","article-title":"Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies","volume":"15","author":"Burt","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.clml.2025.10.014_bib0019","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41408-024-01179-4","article-title":"Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab","volume":"14","author":"Jabbour","year":"2024","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.clml.2025.10.014_bib0020","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood.2024027500","article-title":"Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study","volume":"145","author":"Bassan","year":"2025","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.10.014_bib0021","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2021-146163","article-title":"Frontline consolidation with blinatumomab for high-risk Philadelphia-negative acute lymphoblastic adult patients: early results from the Graall-2014-QUEST Phase 2","volume":"138","author":"Boissel","year":"2021","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2025.10.014_bib0022","first-page":"2481","article-title":"Blinatumomab plus chemotherapy for newly diagnosed B-cell acute lymphoblastic leukemia: results from ECOG-ACRIN E1910","volume":"143","author":"Litzow","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.10.014_bib0023","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.10.014_bib0024","first-page":"365","article-title":"Sequential blinatumomab with reduced-intensity chemotherapy for older adults with newly diagnosed Ph- B-precursor acute lymphoblastic leukemia \u2013 Final results of the ALLG ALL08 study","volume":"7","author":"Fleming","year":"2023","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.10.014_bib0025","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood-2023-174973","article-title":"Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult Ph- B-lineage acute lymphoblastic leukemia: final results of the GIMEMA LAL2317 trial","volume":"142","author":"Chiaretti","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.10.014_bib0026","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-024-01597-8","article-title":"Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial","volume":"17","author":"Lu","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.10.014_bib0027","first-page":"P366","article-title":"Blinatumomab added to prephase and consolidation therapy in newly diagnosed precursor B-ALL in adults: a phase II HOVON trial","volume":"6","author":"Rijneveld","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2025.10.014_bib0028","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2022"},{"key":"10.1016\/j.clml.2025.10.014_bib0029","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2025.10.014_bib0030","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.clml.2025.10.014_bib0031","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (MINORS): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.clml.2025.10.014_bib0032","article-title":"Blinatumomab-based induction therapy for newly diagnosed Philadelphia chromosome\u2013negative B-cell acute lymphoblastic leukemia","volume":"24","author":"Short","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2025.10.014_bib0033","first-page":"1460","article-title":"Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation","volume":"36","author":"Br\u00fcggemann","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2025.10.014_bib0034","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.10.014_bib0035","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Philadelphia chromosome\u2013like acute lymphoblastic leukemia","volume":"129","author":"Pui","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.10.014_bib0036","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.10.014_bib0037","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.clml.2025.10.014_bib0038","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.10.014_bib0039","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2025.10.014_bib0040","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of acute lymphoblastic leukemia in adults: 2024 ELN recommendations","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"16 Suppl","key":"10.1016\/j.clml.2025.10.014_bib0041","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed Ph-negative, CD22-positive B-ALL: alliance A041703","volume":"41","author":"Wieduwilt","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.10.014_bib0042","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2023-180472","article-title":"Dose-reduced chemotherapy in sequence with blinatumomab for older adults with newly diagnosed Ph-negative B-ALL: GMALL study","volume":"142","author":"G\u00f6kbuget","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.10.014_bib0043","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2025.10.014_bib0044","first-page":"2558","article-title":"Measurable residual disease in acute lymphoblastic leukemia","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2025.10.014_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2025.10.014_bib0046","first-page":"1689","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children and young adults","volume":"391","author":"Brown","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.10.014_bib0047","first-page":"87","article-title":"Inotuzumab ozogamicin as first-line therapy in acute lymphoblastic leukemia: rationale for sequential InO followed by blinatumomab (Alliance A041703)","volume":"25","author":"Jabbour","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.10.014_bib0048","article-title":"Advances in the treatment of acute lymphoblastic leukemia: immunotherapy and beyond","volume":"66","author":"Jabbour","year":"2024","journal-title":"Blood Rev"},{"issue":"17","key":"10.1016\/j.clml.2025.10.014_bib0049","first-page":"2746","article-title":"Integrating blinatumomab in the frontline treatment in B-cell acute lymphoblastic leukemia: a new era in therapeutic management","volume":"17","author":"Canichella","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2025.10.014_bib0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bjh.20134","article-title":"The role of blinatumomab in adult acute B-lymphoblastic leukaemia","volume":"207","author":"Wilke","year":"2025","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502504251X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502504251X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:18:13Z","timestamp":1770650293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502504251X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S215226502504251X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cUpfront Use of Blinatumomab in Adolescents and Adults With Philadelphia Chromosome: Negative B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Proportional Meta-Analysis\u201d","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}